Renée Aguiar-Lucander
Not so fast: FDA tacks 3 more months onto decision date for Calliditas' rare kidney disorder drug
It looks like the FDA’s decision on Calliditas’ IgA nephropathy candidate Nefecon is going to take a few months longer than expected — allowing time for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
